Evidence map›Paper›PMID 35839659›Full record

ArticleNeuroImage. Clinical2022

The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow.

Luigi Lorenzini, Silvia Ingala, Alle Meije Wink, Joost P A Kuijer, Viktor Wottschel, Mathijs Dijsselhof, Carole H Sudre, Sven Haller, José Luis Molinuevo, Juan Domingo Gispert and 21 more

Abstract readMulticenter Study
In one paragraph

Article in NeuroImage. Clinical, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Scalable, reproducible, and cost-effective processing of large-scale medical imaging datasets.Proceedings of SPIE--the International Society for Optical Engineering · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Luigi LorenziniDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands. Electronic address: l.lorenzini@amsterdamumc.nl.
Silvia IngalaDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
Alle Meije WinkDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
Joost P A KuijerDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
Viktor WottschelDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Mathijs DijsselhofDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
Carole H SudreMRC Unit for Lifelong Health and Ageing at UCL, London, UK; Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; Centre for Medical Image Computing, University College London, London, UK; School of Biomedical Engineering & Imaging Sciences, King's College London, UK.
Sven HallerCIMC - Centre d'Imagerie Médicale de Cornavin, Place de Cornavin 18, 1201 Genève, Switzerland; Department of Surgical Sciences, Radiology, Uppsala University, Uppsala, Sweden.
José Luis MolinuevoBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; H. Lundbeck A/S, 2500 Valby, Denmark.
Juan Domingo GispertBarcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain; CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain; IMIM (Hospital del Mar Medical Research Institute), Barcelona Spain; Universitat Pompeu Fabra, Barcelona, Spain; CIBER Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Madrid, Spain.
David M CashDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; UK Dementia Research Institute, University College of London, London, UK.
David L ThomasDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology London, UK; Wellcome Centre for Human Neuroimaging, UCL Queen Square Institute of Neurology, London, UK.
Sjoerd B VosCentre for Medical Image Computing, University College London, London, UK; Neuroradiological Academic Unit, UCL Queen Square Institute of Neurology London, UK.
Ferran PradosNuclear Magnetic Resonance Research Unit, Queen Square Multiple Sclerosis Centre, UCL Queen Square Institute of Neurology, London, United Kingdom; Department of Medical Physics and Biomedical Engineering, Centre for Medical Image Computing, University College London, London, United Kingdom; e-Health Centre, Universitat Oberta de Catalunya, Barcelona, Spain.
Jan PetrDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Dresden, Germany.
Robin WolzIXICO, London, UK; Imperial College London, London, UK.
Alessandro PalombitIXICO, London, UK.
Adam J SchwarzTakeda Pharmaceuticals Ltd., Cambridge, MA, USA.
Gaël ChételatUniversité de Normandie, Unicaen, Inserm, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", Institut Blood-and-Brain @ Caen-Normandie, Cyceron, 14000 Caen, France.
Pierre PayouxDepartment of Nuclear Medicine, Toulouse CHU, Purpan University Hospital, Toulouse, France; Toulouse NeuroImaging Center, University of Toulouse, INSERM, UPS, Toulouse, France.
Carol Di PerriCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK.
Joanna M WardlawCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; UK Dementia Research Institute at Edinburgh, University of Edinburgh, UK.
Giovanni B FrisoniLaboratory Alzheimer's Neuroimaging & Epidemiology, IRCCS Instituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; University Hospitals and University of Geneva, Geneva, Switzerland.
Christopher FoleyGE Healthcare Ltd., Little Chalfont, UK.
Nick C FoxDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Craig RitchieCentre for Dementia Prevention, The University of Edinburgh, Scotland, UK.
Cyril PernetCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; Neurobiology Research Unit, Copenhagen University Hospital, Rigshospitalet, Denmark.
Adam WaldmanCentre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK; Department of Brain Sciences, Imperial College London, London, UK.
Frederik BarkhofDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Institute of Neurology and Healthcare Engineering, University College London, London, UK; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
Henk J M M MutsaertsDept. of Radiology and Nuclear Medicine, Amsterdam University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands; Ghent Institute for Functional and Metabolic Imaging (GIfMI), Ghent University, Ghent, Belgium; Amsterdam Neuroscience, Brain Imaging, Amsterdam, The Netherlands.
EPAD consortium

Funding

Department of HealthMedical Research Council MC_UU_00019/2Medical Research Council MC_UU_00019/3Medical Research Council MC_UU_00019/4Medical Research Council MR/J006971/1Wellcome TrustWellcome Trust 539208
6 · The paper itself

Abstract

The European Prevention of Alzheimer Dementia (EPAD) is a multi-center study that aims to characterize the preclinical and prodromal stages of Alzheimer's Disease. The EPAD imaging dataset includes core (3D T1w, 3D FLAIR) and advanced (ASL, diffusion MRI, and resting-state fMRI) MRI sequences. Here, we give an overview of the semi-automatic multimodal and multisite pipeline that we developed to curate, preprocess, quality control (QC), and compute image-derived phenotypes (IDPs) from the EPAD MRI dataset. This pipeline harmonizes DICOM data structure across sites and performs standardized MRI preprocessing steps. A semi-automated MRI QC procedure was implemented to visualize and flag MRI images next to site-specific distributions of QC features - i.e. metrics that represent image quality. The value of each of these QC features was evaluated through comparison with visual assessment and step-wise parameter selection based on logistic regression. IDPs were computed from 5 different MRI modalities and their sanity and potential clinical relevance were ascertained by assessing their relationship with biological markers of aging and dementia. The EPAD v1500.0 data release encompassed core structural scans from 1356 participants 842 fMRI, 831 dMRI, and 858 ASL scans. From 1356 3D T1w images, we identified 17 images with poor quality and 61 with moderate quality. Five QC features - Signal to Noise Ratio (SNR), Contrast to Noise Ratio (CNR), Coefficient of Joint Variation (CJV), Foreground-Background energy Ratio (FBER), and Image Quality Rate (IQR) - were selected as the most informative on image quality by comparison with visual assessment. The multimodal IDPs showed greater impairment in associations with age and dementia biomarkers, demonstrating the potential of the dataset for future clinical analyses.

Indexed as

Alzheimer DiseaseBiomarkersBrainDiffusion Magnetic Resonance ImagingHumansMagnetic Resonance ImagingProdromal SymptomsWorkflowBiomarkersEPADImage analysis pipelineMagnetic resonance imagingMulti-modal data integrationQuality control

Identifiers

PMID35839659
PMCPMC9421463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.